Kornimate/medical-research-clean huggingface dataset:
screening of serum exosomal mirna as a biomarker for ocular muscle myasthenia gravis

Conditions: Myasthenia Gravis

Summary: ocular muscle myasthenia gravis (ocular myasthenia gravis, omg) has a high incidence and is difficult to diagnose. it is very necessary to find specific diagnostic indicators for omg. by collecting peripheral blood of omg, systemic myasthenia gravis and healthy people, extract mirnas derived from exosomes in the serum and perform high-throughput sequencing, then use bioinformatics analysis methods to screen specifically expressed mirnas as biomarkers for omg diagnosis .

part i: (1) collect peripheral blood samples from patients with early-onset omg, early-onset gmg and healthy subjects of age and sex matched who have been diagnosed for the first time and have not undergone any drug treatment. there are 6 cases in each group. extract the secretion mirna in serum and conduct high-throughput sequencing. analyze and compare the differential expression mirnas between omg, gmg and healthy control groups by edger. the standard of differential expression is set as \| logfc \|\>1, p\<0.05. use mirtarbase, targetscan, and mirdb to predict target genes for differentially expressed mirnas. conduct go enrichment and kegg signaling pathway analysis on target genes. the string tool is used to construct the target gene protein interaction network (ppi). according to the importance of the target gene calculated by the maximum population concentration ratio (mcc) method, the top ten genes (hub genes) are selected and analyzed. (2) randomly collect peripheral blood samples from patients with early-onset omg, early-onset gmg, and age-matched healthy subjects, with 10 samples in each group. the differentially expressed mirnas obtained during the sequencing phase were validated using real-time fluorescence quantification (rt-qpcr). construct a receiver operating characteristic curve (roc) curve to evaluate the diagnostic efficacy of the identified mirna.

Eligibility criteria:
inclusion criteria: * clinical manifestations: fluctuating myasthenia; * neostigmine test positive; ③ achr-ab, musk-ab, lrp4-ab antibodies positive; ④repetitive nerve stimulation or single fiber emg positive (comply with the first one of the above diagnostic criteria and any one of the other three, and at the same time exclude ophthalmoplegia caused by other diseases, the diagnosis can be confirmed). exclusion criteria: ①combined with other autoimmune diseases or other inflammatory diseases; ②patients with tumorous diseases; * received targeted biologics, intravenous gamma globulin, plasma exchange therapy within three months before treatment; ④pregnancy status or lactation

Keywords: ocular myasthenia gravis; mirna exosomes
tailored treatment to enhance risk perception in sleep apnea

Conditions: Obstructive Sleep Apnea (OSA)

Summary: obstructive sleep apnea (osa) is seen in approximately 6% of americans. it is a serious medical condition with significant medical and psychological consequences, including diabetes, hypertension, and cardiovascular disease. the treatment of choice for osa is positive airway pressure therapy (pap). pap supplies positive pressure to the upper airway creating a "pneumatic splint" to keep the airway open during sleep. adherence to pap is notoriously low, with as few as 50% reaching minimal guidelines for adherence. one comprehensive review of adherence research found that adherence to pap was less than that for any other medical disorder. the problem of adherence is significant not only because of the medical consequences that can ensue, but also because third party payers have begun to refuse to pay for pap therapy when adherence is less than optimal, even in the face of clinical improvement. this is a critical time to address this problem. this research study is designed to identify methods that may help people respond to pap, the most common therapy for osa. identifying these methods may be an important way to better care for patients with obstructive sleep apnea. with this research, the investigators hope to find ways to help people have a better response to treatment and a better quality of life.


Eligibility criteria:
inclusion criteria: * polysomnography (psg) confirmed diagnosis of obstructive sleep apnea (osa) * choice of pap as preferred treatment * judged by sleep physicians to be responders to pap * participants will be considered responders to pap if they have an ahi of less than 5, do not snore, and have an arousal index of less than 10 when titrated to the proper pressure of pap exclusion criteria: * apnea-hypopnea index (ahi) \< 15 on the diagnostic psg and no daytime functional symptoms or associated cardiovascular disease * a sleep disorder other than osa that causes arousals from sleep (e.g., periodic limb movements, restless legs syndrome, insomnia) * a current substance abuse problem * a serious sleep-disruptive medical condition (e.g., end stage renal failure, severe chronic obstructive pulmonary disease (copd), severe asthma) * significant global cognitive impairment * history of or current diagnosis of psychosis, bipolar disorder, or borderline, schizotypal or antisocial personality disorder, and uncontrolled depression or suicidal ideation * change in antidepressant medications over the past 3 months * women pregnant women, breast feeding, or planning on becoming pregnant * currently enrolled in another research study
art for ms - controlled trial

Conditions: Multiple Sclerosis; Fatigue

Summary: this study is a controlled pilot study with 17 participants with multiple sclerosis (ms). the primary goal of this study is to objectively examine the effects of a multimodal dance intervention on walking-related performance fatigability. the secondary aim is to investigate the effects of a multimodal dance intervention on other ms symptoms related to fatigue and fatigability. the following research questions will be addressed: 1. does a multimodal dance intervention have positive effects on walking-related fatigability? 2. does a multimodal dance intervention have positive effects on other ms symptoms related to fatigue and fatigability?

this study distinguish two groups contributing to a dance and art production. the experimental group will perform 10 weeks of dance training, while the other group will contribute to the production in various ways (e.g. word art, photography, painting, ...). measures will be taken before and after the training or assistance in the production.

Eligibility criteria:
inclusion criteria: * age between 18 - 70 years * confirmed diagnosis according to the mcdonald criteria * able to walk independently or with bilateral support for 6 minutes * signed the informed consent exclusion criteria: * exacerbation or relapse within last 3 months before onset study * other medical conditions interfering with walking ability (e.g. cardiac or respiratory diseases, arthritis, fibromyalgia, parkinson and stroke)

Keywords: multiple sclerosis fatigue
clinical study of pegylated somatropin to treat children growth hormone deficiency

Conditions: Growth Hormone Deficiency

Summary: to evaluate the safety and efficacy of peg somatropin injection (jintrolong®) in the treatment of short stature due to endogenous growth hormone deficiency (ghd) in the broad of population of children.


Eligibility criteria:
inclusion criteria: * before starting treatment, the child is diagnosed as ghd according to medical history,clinical symptoms and signs, gh provocation tests and imaging examinators and other examinators. * according to the height statistical data of chinese children's physical development in nine cities in 2015, the height of the child is lower than the third percentile of normal children's growth curve in the same age and same gender. * height velocity (hv) ≤5.0 cm/yr. * gh provocation tests with two different mechanisms showed that gh peak concentration of the child is \< 10.0ng/ml. * bone age (ba) ≤9 years in girls or ≤ 10 years in boys, and the ba is 1 year less than the ca. * prepuberty status (tanner i stage), age ≥3 years old, girls and boys are acceptable. * the child did not receive the treatment of growth hormone within 6 months. * subjects are willing and able to cooperate to complete scheduled visits, treatment plans and laboratory tests and other procedures, and they sign informed consent. exclusion criteria: * the child is dysfunction of liver and kidney (alt) 2 times of the upper limit of normal value, cr\> the upper limit of normal value). * the child has positive hepatitis b core antibody (hbc), hepatitis b surface antigen (hbsag) and hepatitis b e antigen (hbeag). * the child is known as hypersensitivity to peg somatropin. * the child has severe cardiopulmonary, hematological diseases, malignant tumors, general infection or immunodeficiency diseases. * the child has potential tumor (family history). * the child has diabetics. * the child has abnormal growth and development, such as turner's syndrome, constitutional delay of growth and puberty, laron syndrome, growth hormone receptor deficiency, short stature girls with potential chromosomal abnormalities. * the child took part in other clinical trials within 3 months. * other conditions are excluded when the investigator preclude the enrollment into the study.
quetiapine induced neuroplasticity in first-episode schizophrenic patients

Conditions: Schizophrenia

Summary: aim of the study is to assess the effect of quetiapine treatment in neuroleptic naive, first-episode schizophrenic patients on aspects of functional and structural neuroplasticity assessed by means of transcranial magnetic stimulation and voxel-based morphometry. main outcome measure is a change in gray matter density under quetiapine treatment from baseline to steady-state-treatment after 3 weeks.


Eligibility criteria:
inclusion criteria: * diagnosis of first episode of schizophrenia according to diagnostic and statistical manual of mental disorders- fourth edition (dsm-iv) criteria and no history of neuroleptic medication * females and/or males aged 18 to 65 years * mild to moderate schizophrenia exclusion criteria: * neuroleptic treatment prior to study enrollment * pregnancy or lactation * any dsm-iv axis i disorder not defined in the inclusion criteria * patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others * known intolerance or lack of response to quetiapine fumarate as judged by the investigator * use of any of the following cytochrome p450 3a4 inhibitors in the 14 days preceding enrolment including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine and saquinavir * use of any of the following cytochrome p450 inducers in the 14 days preceding enrolment including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, st. john's wort, and glucocorticoids * any history of neuroleptic treatment * substance or alcohol dependence at enrollment (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by dsm-iv criteria * opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by dsm-iv criteria within 4 weeks prior to enrollment * medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment * unstable or inadequately treated medical illness (e.g. angina pectoris, hypertension, congestive heart failure) as judged by the investigator * involvement in the planning and conduct of the study * history of or evidence of significant brain malformation or neoplasm, head injury, cerebral vascular events, neurodegenerative disorder affecting the brain or prior brain surgery * concomitant treatment with psychotropic drugs (e.g. antidepressive agents, anticonvulsants, other neuroleptics) except benzodiazepines or hypnotics
n-acetylcysteine for tobacco use disorder

Conditions: Nicotine Dependence; Smoking

Summary: the purpose of this study is to assess the effects of administering n-acetylcysteine (nac) to assist in initial cessation and/or relapse prevention in adult cigarette smokers.

the aim of this study is to assess the effects of n-acetylcysteine (nac) on initial cessation and relapse prevention in adult cigarette smokers. specifically, this study has the following aims: aim 1) examine the efficacy of nac, compared to placebo, in helping smokers achieve three days of continuous abstinence; aim 2) among those who maintain initial 3-day abstinence, examine the time to relapse over the 8-week intervention between nac and placebo groups; aim 3) assess 7-day point prevalence abstinence at the 8-week end-of-treatment study visit in order to obtain effect sizes and estimates of variability to power a randomized clinical trial.

Eligibility criteria:
inclusion criteria: 1. age 18-65 2. daily smoker for ≥6 months, smoking approximately ≥5 cigarettes per day on average in the past month or must meet the criteria for nicotine dependence 3. be interested in quitting smoking (defined as a 2 or above on a 10-point likert scale assessing readiness and interest in quitting (1=not at all ready/interested, 10=extremely ready/interested) 4. willing to engage in a 3-day quit attempt as part of study procedures 5. willing to abstain from cannabis use during study procedures (since inhaled cannabis will affect breath carbon monoxide readings). 6. if female, agreement to use birth control (any form) to avoid pregnancy during study procedures exclusion criteria: 1. any serious or unstable medical/psychiatric disorder (including severe substance use disorders, other than tobacco use disorder) in the past month that may interfere with study performance based on pi judgment 2. current pregnancy or breastfeeding 3. current use of medications with smoking cessation efficacy 4. known hypersensitivity to nac 5. use of carbamazepine or nitroglycerin (or any other medication deemed to be hazardous if taken with nac) within 14 days of study participation

Keywords: nicotine tobacco smoking cessation n-acetylcysteine nac pharmacotherapy relapse tobacco use disorder
antibiotic concentration after delivery to middle ear for chronic suppurative otitis media

Conditions: Chronic Suppurative Otitis Media

Summary: the study team aims to elucidate the potential role of ototopical antibiotic concentration on outcomes in patients diagnosed with chronic suppurative otitis media (csom). chronic suppurative otitis media (csom) is characterized by chronic inflammation of the middle ear with persistent discharge from a non-intact tympanic membrane. csom is notably associated with a significant burden of disease worldwide. topical fluoroquinolones are first line therapy for csom and are advantageous as compared to oral or intravenous therapy in that these antibiotics avoid systemic side effects and have the potential to locally deliver high antibiotic concentrations, which were thought to be sufficient to overcome all bactericidal resistance to fluoroquinolones. the investigators will measure antibiotic concentration in aspirates via liquid chromatography with tandem mass spectrometry (lc-ms/ms) from the middle ear of selected subjects with csom who are prescribed and instructed to self-administer ototopical ciprofloxacin. enrolled subjects will be asked to return 3 to 10 days after initial visit to aspirate the middle ear and receive a follow-up evaluation. furthermore, the subjects will be asked to keep logs of their medication use and to administer the ototopical medication one hour prior to their appointments. the measured ciprofloxacin concentrations will be correlated with clinical outcomes, primarily the time to symptom resolution. the guiding hypothesis is that patient self-administration of ciprofloxacin drops vary in antibiotic delivery with diluted concentrations significantly below the in vitro concentration of the prescribed solution and that these concentrations are below the bactericidal concentration of ciprofloxacin-resistant bacteria.


Eligibility criteria:
inclusion criteria: * adult patients greater than or equal to 18 years of age * diagnosis of chronic suppurative otitis media (csom) exclusion criteria: * atypical presentation of csom or atypical anatomy of the ear * presence of additional ear pathophysiology beyond csom * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * pregnant women * prisoners * non-english speaking

Keywords: csom antibiotic resistance chronic suppurative otitis media ototopical ciprofloxacin
electrophysiological recording for patients receiving deep brain stimulation electrode for treatment-resistant obsessive-compulsive disorder

Conditions: Obsessive-compulsive Disorder

Summary: the purpose of this project is to study live recordings from neuronal population of the human nucleus accumbens during the implantation of deep brain stimulation (dbs) electrodes for the treatment-resistant obsessive compulsive disorder (ocd). the central aim of this project is to determine if intra-operative electrophysiological data can confirm that the electrode is located in the nucleus accumbens. this confirmation could allow the placement of the dbs electrodes with a higher degree of precision. an additional aim of this project will be to study the activity of the neuronal population of the nucleus accumbens while a subject is presented with a task involving an unexpected reward. the investigators central hypothesis is that unexpected reward will be associated with increase firing and synchrony in the neuronal population. this will translate into recordable increase activity in the investigators region of interest and therefore confirm the proper placement of the electrode. this study enrolled 2 subjects, with 1 subject completing the protocol showing the feasibility of the experiment. there were electrophysiological variations with the task presented but no conclusion could be drawn given the small sample size.


Eligibility criteria:
inclusion criteria: * treatment-resistant ocd * failure of psychotherapy * failure of pharmacotherapy * meets inclusion criteria for dbs implant in ocd exclusion criteria: * significant substance use disorder * significant personality disorder

Keywords: treatment resistant obsessive-compulsive disorder
study of the combination of cm082 with everolimus in patients with mrcc

Conditions: Renal Cell Carcinoma Recurrent

Summary: this is a phase i dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of cm082 in combination with everolimus in chinese patients with advanced renal cell carcinoma.

this is a phase i dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of cm082 in combination with everolimus in chinese patients with renal cell carcinoma (rcc). after the maximum tolerated dose (mtd) or the optimal biological dose is identified, an expansion cohort of \~10 advanced renal cell carcinoma patients will be enrolled to further characterize the safety and tumor response by ct.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of clear cell renal cell carcinoma * progressed on at least one standard therapy * measurable disease per recist1.1 * eastern cooperative group (ecog) performance status score of 0 or 1 * life expectancy of at least 12 weeks * no abnormal bone marrow function * adequate heart, lung, liver, kidney organ system functions, and meet the following requirements: * total bilirubin ≤1.5 times the upper limit of normal (uln) * alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤1.5x the upper limit of normal (uln) if no liver involvement or ≤5x the upper limit of normal with liver involvement. * creatinine ≤ 1.5 x uln * urine protein \<1+ * qtcf \< 450 ms * lvef ≥ 50% * at least 4 weeks after receiving cancer therapy (i.e., chemotherapy, radiation therapy, biologic therapy, hormonal therapy); 3 months after surgery and recovered * willingness and ability to comply with trial and follow-up procedures * ability to understand the nature of this trial and give written informed consent exclusion criteria: * currently receiving anti-cancer treatment * other tumors in addition to renal cell carcinoma * have taken strong cytochrome p450 3a4 inhibitors or inducers in the last 2 weeks * concomitant use of drugs with a risk of causing prolonged corrected qt interval and/or torsades de pointes * patients with a history of intolerance to, or significant toxicity with vegfr tyrosine kinase inhibitor(s) (tki) or everolimus * females who are pregnant or breastfeeding * those in reproductive ages who refuse to use contraception * those with concurrent condition(e.g. psychological, neuronal, cardiovascular, respiratory conditions or infections) that in the investigator's opinion would jeopardize compliance with the protocol * patients with known central nervous system (cns) metastases * presence of active gastrointestinal (gi) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of cm082 or everolimus * patients with known severe lung disorders such as asthma, chronic obstructive pulmonary disease (copd) * patients who are hiv positive * drug or alcohol abuser
tandemheart to reduce infarct size (tris trial)

Conditions: Acute Myocardial Infarction

Summary: the purpose of this study is to determine if a device known as the tandemheart® system (tandemheart) can help limit heart damage and reduce serious complications after a certain type of heart attack (acute st elevation anterior wall myocardial infarction \[stemi\]) by evaluating the use of the tandemheart system prior to a procedure called percutaneous coronary intervention (pci)


Eligibility criteria:
inclusion criteria the following is a list of general inclusion criteria. more detailed information can be found in the study protocol. 1. ≥ 18 years of age 2. presents within 6 hours of acute mi symptoms 3. evidence of st elevation 4. first myocardial infarction 5. written informed consent exclusion criteria the following is a list of general exclusion criteria. more detailed information can be found in the study protocol. 1. contraindications to antiplatelet/anticoagulation therapy 2. history of blood disorders or active bleeding 3. renal dysfunction or failure 4. neurologic damage 5. cardiogenic shock 6. history of cerebrovascular disease 7. history of transfusion reaction 8. prior coronary artery bypass surgery 9. participation in another trial with an investigational drug or device 10. pregnant

Keywords: myocardial infarction stemi st elevation mi acute mi